Hematological malignancies, encompassing a diverse range of leukemias and lymphomas, have been at the forefront of mass cytometry applications. The ability to analyze multiple parameters simultaneously at the single-cell level has revolutionized our understanding of these diseases, from classification to treatment monitoring. Let’s explore how mass cytometry is reshaping the landscape of hematological oncology.
Leukemia and Lymphoma Classification
Traditional classification methods for leukemias and lymphomas relied on a limited set of markers. Mass cytometry has dramatically expanded our ability to characterize these malignancies with unprecedented detail.
The landmark study by Amir et al. (2013) introduced viSNE, a tool for visualizing high-dimensional single-cell data. Applied to leukemia samples, viSNE revealed phenotypic heterogeneity that was previously undetectable, demonstrating the power of mass cytometry in refining disease classification. Thereafter, Amir launched his own data analysis company, Astrolabs.
A recent breakthrough came from Hansmann et al. (2022) in Nature Medicine, titled “Single-cell proteomic profiling identifies distinct tumor-associated macrophage subsets in diffuse large B cell lymphoma.” Using a 42-marker mass cytometry panel, they uncovered novel macrophage subsets with prognostic significance in diffuse large B cell lymphoma, potentially opening new avenues for targeted therapies.
Restricted content
You must be logged in and have a valid subscription to see this content. Please visit our subscription page for more info. If you are already a VIP member, be sure you are logged in with the same email address you made your purchase.
Hematology and CyTOF? Now that's a match made in scientific heaven. It's like liquid biopsies were designed with CyTOF in mind - no clogging, no fuss, just cells living their best life in suspension. Sure, we can image lymph nodes on the Hyperion, but let's face it, blood samples are the smooth operators of the cellular world. They glide through the CyTOF like a hot knife through butter. But here's the kicker: we're sitting on a gold mine of hematology data, and we're barely scratching the surface. It's like having a library full of books and only reading the covers. Routine biopsies, Matutes scores, flow cytometry data - it's all there, begging to be recycled, reused, and reimagined through the lens of CyTOF. Imagine if we could turn every routine blood test into a treasure trove of research potential. It's not just possible - it's practically begging to happen. We just need to stop treating our data like a one-hit wonder and start seeing it as the gift that keeps on giving.
